Apatinib with standard care for advanced breast cancer
Part of Cancer clinical trials.
This study tests whether adding the drug apatinib mesylate to your doctor's chosen treatment can help slow or shrink advanced breast cancer. It's for people whose cancer has continued to grow despite prior hormonal therapy and CDK4/6 inhibitor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of breast cancer that is HER2-negative and hormone-receptor-positive (HR-positive).
- You must have had prior chemotherapy that included an anthracycline or a taxane (like doxorubicin or paclitaxel).
- You must have previously been treated with endocrine therapy and a CDK4/6 inhibitor (like palbociclib, ribociclib) for advanced disease, and your cancer has progressed.
- You can have had no more than 3 prior chemotherapy lines for advanced or recurrent breast cancer.
- Your cancer must be active as seen on a PET-CT scan (SUV > 5), and you must have at least one measurable tumor that hasn't been surgically removed or radiated.
- You must be 18 or older, have good performance status (ECOG 0-1), and have adequate organ function (kidney, liver, blood counts, and blood clotting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests a combination of two oral drugs, TAS-102 and apatinib, as a third-line treatment for advanced stomach cancer. It aims to see if this combination can help control the cancer when other treatments have not worked.
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
This trial tests a pill called apatinib in people whose cancer has spread to the belly and causes fluid to build up (malignant ascites). Apatinib works by cutting off the blood supply that tumors need to grow, which may help reduce the fluid and ease symptoms.
This trial tests a combination of two drugs for advanced stomach, gastroesophageal junction, or colorectal cancer. The drugs work in different ways to attack cancer cells and may help slow down the disease.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.